Patents by Inventor David Knight

David Knight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Micro Diaphragm Pump
    Publication number: 20090112155
    Abstract: The invention relates to micropumps for infusing fluids. More specifically, the present disclosure describes and illustrates a micropump design that may be useful for infusing insulin into a diabetic patient. The disclosed design employs a pump chamber that has a diaphragm and a plurality of check valves that are configured to avoid leakage from the reservoir through the pump engine and into an infusion device and, also, to ensure the complete, accurate evacuation of the pump chamber.
    Type: Application
    Filed: October 30, 2008
    Publication date: April 30, 2009
    Applicant: LifeScan, Inc.
    Inventors: Mitch Zhao, Peter Krulevitch, David Knight, Anthony Lam, Sean O'Connor
  • THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS
    Publication number: 20090082349
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones.
    Type: Application
    Filed: March 2, 2007
    Publication date: March 26, 2009
    Inventors: Dashyant Dhanak, Steven David Knight
  • THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS
    Publication number: 20090048252
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones.
    Type: Application
    Filed: March 2, 2007
    Publication date: February 19, 2009
    Inventors: Dashyant Dhanak, Steven David Knight
  • Compounds, compositions and methods
    Patent number: 7491746
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: February 17, 2009
    Assignees: Cytokinetics, Inc., SmithKline Beecham Corporation
    Inventors: Andrew McDonald, Gustave Bergnes, Bainian Feng, David J. Morgans, Jr., Steven David Knight, Kenneth A. Newlander, Dashyant Dhanak, Christopher A. Brook
  • Compounds, methods and compositions
    Patent number: 7482343
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: January 27, 2009
    Assignees: Cytokinetics, Inc., SmithKline Beecham Corporation
    Inventors: Han-Jie Zhou, David J. Morgans, Jr., Gustave Bergnes, Steven David Knight, Kenneth A. Newlander, Dashyant Dhanak, Nicholas D. Adams
  • THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS
    Publication number: 20090023742
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of substituted thiazolones.
    Type: Application
    Filed: March 2, 2007
    Publication date: January 22, 2009
    Inventors: Dashyant Dhanak, Steven David Knight
  • Methods of treating a blood pathology using anti-TNF antibodies and fragments thereof
    Publication number: 20090022718
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: December 7, 2007
    Publication date: January 22, 2009
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS
    Publication number: 20090018131
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.
    Type: Application
    Filed: June 12, 2008
    Publication date: January 15, 2009
    Inventors: Nicholas D. ADAMS, Joelle Lorraine BURGESS, Michael Gerard DARCY, Steven David KNIGHT, Kenneth Allen NEWLANDER, Lance H. RIDGERS, Stanley J. SCHMIDT
  • Compounds, compositions, and methods
    Patent number: 7476743
    Abstract: 1,2,4-Tiazole-5-ones useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: January 13, 2009
    Assignees: Cytokinetics, Inc., SmithKline Beecham Corporation
    Inventors: Xiangping Qian, Gustave Bergnes, David J. Morgans, Jr., Steven David Knight, Dashyant Dhanak
  • Compounds, compositions and methods
    Publication number: 20090005580
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Application
    Filed: June 19, 2008
    Publication date: January 1, 2009
    Inventors: Andrew McDonald, Gustave Bergnes, Bainian Feng, David J. Morgans, JR., Steven David Knight, Kenneth A. Newlander, Dashyant Dhanak, Christopher A. Brook
  • Anti-IL-6 Antibodies, Compositions, Methods and Uses
    Publication number: 20080312172
    Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Application
    Filed: October 30, 2007
    Publication date: December 18, 2008
    Inventors: Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
  • QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
    Publication number: 20080300239
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.
    Type: Application
    Filed: May 16, 2008
    Publication date: December 4, 2008
    Inventors: Nicholas D. Adams, Joelle Lorraine Burgess, Michael Gerrard Darcy, Carla A. Donatelli, Steven David Knight, Kenneth Allen Newlander, Lance Ridgers, Martha A. Sarpong, Stanley J. Schmidt
  • QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS
    Publication number: 20080293706
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.
    Type: Application
    Filed: May 8, 2008
    Publication date: November 27, 2008
    Inventors: Amita CHAUDHARI, Dashyant DHANAK, Carla Ann DONATELLI, Thomas H. FAITG, Yanhong FENG, Steven David KNIGHT, Cynthia A. PARRISH, Jeffrey M. RALPH
  • THIAZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS
    Publication number: 20080255115
    Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using thiazolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivatives.
    Type: Application
    Filed: August 24, 2007
    Publication date: October 16, 2008
    Inventors: Michael Gerard Darcy, Steven David Knight, Nicholas D. Adams, Stanley J. Schmidt
  • Methods of inhibiting TNF? activity in the blood of a patient
    Patent number: 7425330
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: September 16, 2008
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Methods of treating rheumatoid arthritis with anti-TNF antibodies
    Patent number: 7416729
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: August 26, 2008
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • METHODS AND APPARATUSES FOR RECORDING AN AUDIO CONFERENCE
    Publication number: 20080183467
    Abstract: In one embodiment, the systems and methods detect audio content shared during a collaboration session; detect a participant associated with originating the audio content; store or record audio content; and automatically associate the audio content with the participant.
    Type: Application
    Filed: January 25, 2007
    Publication date: July 31, 2008
    Inventors: (Eric) Zheng Yuan, David Knight, Shawn Farshchi, Eric Montoya
  • Methods of inhibiting or neutralizing TNF? in patients with tissue injury
    Patent number: 7404955
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: July 29, 2008
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Compounds, Compositions, and Methods
    Publication number: 20080176830
    Abstract: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
    Type: Application
    Filed: April 13, 2006
    Publication date: July 24, 2008
    Inventors: Nicholas D. Adams, Michael Gerard Darcy, Dashyant Dhanak, Kevin J. Duffy, Duke M. Fitch, Steven David Knight, Kenneth Allen Newlander, Antony N. Shaw
  • METHODS AND APPARATUSES FOR DYNAMICALLY SUGGESTING AN APPLICATION BASED ON A COLLABORATION SESSION
    Publication number: 20080168140
    Abstract: In one embodiment, the methods and apparatuses detect shared content during a collaboration session; detect a content type based on the shared content; suggest an application based on the content type; and initiate the application during the collaboration session.
    Type: Application
    Filed: January 22, 2007
    Publication date: July 10, 2008
    Inventors: Weidong Chen, Lei Zhu, Min Zhu, Chris Kangas, Matthew Sheppard, David Knight